e-learning
resources
Vienna 2009
Tuesday, 15.09.2009
Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of bronchial thermoplasty (BT) in patients with severe asthma: the AIR2 trial
G. Cox, A. Rubin, M. Laviolette, I. Pavord, N. Thomson (Hamilton, Quebec, Canada; Porto Alegre, Brazil; Leicester, Glasgow, United Kingdom)
Source:
Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009
Session:
Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009
Session type:
Oral Presentation
Number:
3044
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Cox, A. Rubin, M. Laviolette, I. Pavord, N. Thomson (Hamilton, Quebec, Canada; Porto Alegre, Brazil; Leicester, Glasgow, United Kingdom). Efficacy of bronchial thermoplasty (BT) in patients with severe asthma: the AIR2 trial. Eur Respir J 2009; 34: Suppl. 53, 3044
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial
Source: Annual Congress 2011 - New treatments for airway disease
Year: 2011
Indirect comparison of bronchial thermoplasty (BT) versus omalizumab (OM) for severe uncontrolled asthma
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial
Source: Eur Respir J 2007; 30: 457-466
Year: 2007
Clinical response of severe asthma patients following Bronchial Thermoplasty.
Source: International Congress 2017 – To freeze or heat?
Year: 2017
Cost effectiveness of bronchial thermoplasty for treatment of severe asthma patients in spain
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Safety of bronchial thermoplasty (bt), a novel procedure for severe asthma; positive safety profile in the air2 trial
Source: Annual Congress 2009 - Treatment beyond inhalers
Year: 2009
Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Towards optimal patient selection for bronchial thermoplasty treatment in severe asthma: results from the TASMA randomized trial
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands
Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care
Year: 2007
Inhaled corticosteroids in patients with mild to moderate COPD with and without airway hyperresponsiveness to mannitol: A randomized placebo controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016
Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015
Efficacy of symbicort administration in patients with bronchial asthma
Source: Annual Congress 2009 - Treatment of airways disease
Year: 2009
Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept